Experimental dengue vaccine protects all recipients in virus challenge study
3 institutional releases
Published in Science Translational Medicine · View the paper (DOI)
A clinical trial showed that the experimental vaccine TV003 protected all 21 volunteers from infection, while placebo recipients developed infection. The study's results inform a phase 3 efficacy trial and offer new hope for dengue prevention.
Coverage from 3 institutions
- Experimental dengue vaccine protects all recipients in virus challenge study NIH/National Institute of Allergy and Infectious Diseases · Mar 16, 2016 · first to report
- Vermont Vaccine Testing Center study reveals effective, single-dose dengue vaccine University of Vermont · Mar 16, 2016
- Human challenge promises to speed up dengue vaccine development American Association for the Advancement of Science (AAAS) · Mar 16, 2016